More News! 19 May 2017
The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection
Hansa Medical has accessed the EMA’s priority medicines scheme to accelerate the development of a therapy that broadens the access to kidney transplants. Hansa Medical, based in Lund, Sweden, develops enzymes with immunomodulatory properties. Its lead candidate, IdeS, has now been granted access to the EMA’s priority medicines (PRIME) scheme, designed to support the development […]